COMMON INITIAL DOSING REGIMENS

• 250–1,000 mcg intranasally, administered 1–2 times daily.

MECHANISM OF ACTION

• Selank modulates the immune system and neurotransmitter activity, particularly by regulating serotonin levels. It enhances brain-derived neurotrophic factor (BDNF), which supports cognitive function and neuronal health. Selank’s anti-anxiety effects are linked to its ability to stabilize enkephalins, endogenous peptides involved in stress response.

COMMON SIDE EFFECTS

• Mild: Nasal irritation or mild headaches.

• Neurological: Rare cases of drowsiness or overstimulation.

• Immunological: No significant long-term side effects have been reported, but data is limited.

• Rare: Hypersensitivity reactions or transient mood alterations.

CONTRAINDICATIONS

• Absolute: Hypersensitivity to Selank or its formulation components.

• Relative: Patients with autoimmune disorders should use caution due to its immunomodulatory effects. Its safety profile in pregnant or breastfeeding women has not been established.

DISCLAIMER

• Selank is not FDA-approved and is considered experimental outside specific regulatory approvals in Russia.

MORE INFORMATION

• FDA Safety Data Sheet not available (experimental peptide).